Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol)...(te calcium) indicated in combination wit...)

Date:2/27/2008

te calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation; and Bystolic(TM) (nebivolol), a beta-adrenergic receptor blocking agent indicated for the treatment of hypertension. In addition to our growing product line, Forest also co-promotes the Daiichi Sankyo, Inc. products Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker; Benicar HCT(R)* (olmesartan medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product; and AZOR(TM)* (amlodipine and olmesartan medoxomil), a calcium channel blocker and angiotensin receptor blocker combination product, all indicated for the treatment of hypertension.

* Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are

registered trademarks of Daiichi Sankyo, Inc.; and Campral is a

registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,

Darmstadt, Germany.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform act of 1995, including with regard to the future value of the product and the anticipated economic impact of the transaction. These statements involve a number of risks and uncertainties, including regulatory matters outside of the companies' control, the acceptance and demand for Bystolic, the impact of competitive products and pricing, and the risk factors listed from time to time in Forest Laboratories' Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.

'/>"/>

SOURCE Forest Laboratories, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
2. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
3. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
4. Nanotube forests grown on silicon chips for future computers, electronics
5. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
6. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
7. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
8. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
9. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
11. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems